| 30389923 |
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Ip, CKM,
Ng, PKS,
Jeong, KJ,
Shao, SH,
Ju, Z,
Leonard, PG,
Hua, X,
Vellano, CP,
Woessner, R,
Sahni, N,
Scott, KL,
Mills, GB
|
Nat Commun |
2018 |
| 22665524 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors
Heinrich, MC,
Mariño-Enríquez, A,
Presnell, A,
Donsky, RS,
Griffith, DJ,
McKinley, A,
Patterson, J,
Taguchi, T,
Liang, CW,
Fletcher, JA
|
Mol. Cancer Ther. |
2012 |
| 15928335 |
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
Corless, CL,
Schroeder, A,
Griffith, D,
Town, A,
McGreevey, L,
Harrell, P,
Shiraga, S,
Bainbridge, T,
Morich, J,
Heinrich, MC
|
J. Clin. Oncol. |
2005 |
| 29093181 |
A precision therapy against cancers driven by KIT/PDGFRA mutations
Evans, EK,
Gardino, AK,
Kim, JL,
Hodous, BL,
Shutes, A,
Davis, A,
Zhu, XJ,
Schmidt-Kittler, O,
Wilson, D,
Wilson, K,
DiPietro, L,
Zhang, Y,
Brooijmans, N,
LaBranche, TP,
Wozniak, A,
Gebreyohannes, YK,
Schöffski, P,
Heinrich, MC,
Deangelo, DJ,
Miller, S,
Wolf, B,
Kohl, N,
Guzi, T,
Lydon, N,
Boral, A,
Lengauer, C
|
Sci Transl Med |
2017 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Smith, BD,
Kaufman, MD,
Lu, WP,
Gupta, A,
Leary, CB,
Wise, SC,
Rutkoski, TJ,
Ahn, YM,
Al-Ani, G,
Bulfer, SL,
Caldwell, TM,
Chun, L,
Ensinger, CL,
Hood, MM,
McKinley, A,
Patt, WC,
Ruiz-Soto, R,
Su, Y,
Telikepalli, H,
Town, A,
Turner, BA,
Vogeti, L,
Vogeti, S,
Yates, K,
Janku, F,
Abdul Razak, AR,
Rosen, O,
Heinrich, MC,
Flynn, DL
|
Cancer Cell |
2019 |
